Next Article in Journal
Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy
Next Article in Special Issue
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
Previous Article in Journal
An In Silico Identification of Common Putative Vaccine Candidates against Treponema pallidum: A Reverse Vaccinology and Subtractive Genomics Based Approach
Previous Article in Special Issue
Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(2), 404; doi:10.3390/ijms18020404

Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways

School of Life Science and Technology, Harbin Institute of Technology, Harbin 150080, China
*
Author to whom correspondence should be addressed.
Academic Editor: William Chi-shing Cho
Received: 23 December 2016 / Revised: 7 February 2017 / Accepted: 7 February 2017 / Published: 14 February 2017
(This article belongs to the Special Issue Targeting Immune Checkpoints and Immunotherapy)
View Full-Text   |   Download PDF [1668 KB, uploaded 14 February 2017]   |  

Abstract

Malignant cancers employ diverse and intricate immune evasion strategies, which lead to inadequately effective responses of many clinical cancer therapies. However, emerging data suggest that activation of the tolerant innate immune system in cancer patients is able, at least partially, to counteract tumor-induced immunosuppression, which indicates triggering of the innate immune response as a novel immunotherapeutic strategy may result in improved therapeutic outcomes for cancer patients. The promising innate immune targets include Toll-like Receptors (TLRs), RIG-I-like Receptors (RLRs), and Stimulator of Interferon Genes (STING). This review discusses the antitumor properties of TLRs, RLRs, and STING-mediated innate immune pathways, as well as the promising innate immune targets for potential application in cancer immunotherapy. View Full-Text
Keywords: cancer immunotherapy; innate immunity; Toll-like Receptors; RIG-I-like Receptors; Stimulator of Interferon Genes cancer immunotherapy; innate immunity; Toll-like Receptors; RIG-I-like Receptors; Stimulator of Interferon Genes
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Li, K.; Qu, S.; Chen, X.; Wu, Q.; Shi, M. Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways. Int. J. Mol. Sci. 2017, 18, 404.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top